These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17401089)

  • 1. Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT.
    Leroy C; Comtat C; Trébossen R; Syrota A; Martinot JL; Ribeiro MJ
    J Nucl Med; 2007 Apr; 48(4):538-46. PubMed ID: 17401089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
    Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
    J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of serotonin transporter availability with [11C]MADAM--a comparison between the ECAT HRRT and HR systems.
    Schain M; Tóth M; Cselényi Z; Stenkrona P; Halldin C; Farde L; Varrone A
    Neuroimage; 2012 Mar; 60(1):800-7. PubMed ID: 22227138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility.
    Hirvonen J; Johansson J; Teräs M; Oikonen V; Lumme V; Virsu P; Roivainen A; Någren K; Halldin C; Farde L; Hietala J
    J Cereb Blood Flow Metab; 2008 May; 28(5):1059-69. PubMed ID: 18183028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
    Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
    J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rostrocaudal gradients of dopamine D2/3 receptor binding in striatal subregions measured with [(11)C]raclopride and high-resolution positron emission tomography.
    Alakurtti K; Johansson JJ; Tuokkola T; Någren K; Rinne JO
    Neuroimage; 2013 Nov; 82():252-9. PubMed ID: 23727314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.
    Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
    Biol Psychiatry; 2005 Feb; 57(3):229-38. PubMed ID: 15691523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I.
    Shingai Y; Tateno A; Arakawa R; Sakayori T; Kim W; Suzuki H; Okubo Y
    Ann Nucl Med; 2014 Apr; 28(3):220-6. PubMed ID: 24385293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal and extrastriatal dopamine transporter in cannabis and tobacco addiction: a high-resolution PET study.
    Leroy C; Karila L; Martinot JL; Lukasiewicz M; Duchesnay E; Comtat C; Dollé F; Benyamina A; Artiges E; Ribeiro MJ; Reynaud M; Trichard C
    Addict Biol; 2012 Nov; 17(6):981-90. PubMed ID: 21812871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders.
    Appel L; Jonasson M; Danfors T; Nyholm D; Askmark H; Lubberink M; Sörensen J
    J Nucl Med; 2015 Feb; 56(2):234-42. PubMed ID: 25593112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study.
    Jucaite A; Odano I; Olsson H; Pauli S; Halldin C; Farde L
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):657-68. PubMed ID: 16514530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates.
    Varrone A; Stepanov V; Nakao R; Tóth M; Gulyás B; Emond P; Deloye JB; Vercouillie J; Stabin MG; Jonsson C; Guilloteau D; Halldin C
    J Nucl Med; 2011 Aug; 52(8):1313-21. PubMed ID: 21764797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand.
    Varrone A; Steiger C; Schou M; Takano A; Finnema SJ; Guilloteau D; Gulyás B; Halldin C
    Synapse; 2009 Oct; 63(10):871-80. PubMed ID: 19562698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[β-(11)C]DOPA and [(18)F]FE-PE2I in humans.
    Suzuki M; Ito H; Kodaka F; Takano H; Kimura Y; Fujiwara H; Sasaki T; Takahata K; Nogami T; Nagashima T; Nengaki N; Kawamura K; Zhang MR; Varrone A; Halldin C; Okubo Y; Suhara T
    Nucl Med Commun; 2014 Mar; 35(3):231-7. PubMed ID: 24468851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET.
    Saba W; Valette H; Schöllhorn-Peyronneau MA; Coulon C; Ottaviani M; Chalon S; Dolle F; Emond P; Halldin C; Helfenbein J; Madelmont JC; Deloye JB; Guilloteau D; Bottlaender M
    Synapse; 2007 Jan; 61(1):17-23. PubMed ID: 17068778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of dopamine transporters in human brain using [11C]PE2I and positron emission tomography: evaluation of reference tissue models.
    Seki C; Ito H; Ichimiya T; Arakawa R; Ikoma Y; Shidahara M; Maeda J; Takano A; Takahashi H; Kimura Y; Suzuki K; Kanno I; Suhara T
    Ann Nucl Med; 2010 May; 24(4):249-60. PubMed ID: 20364374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HRRT versus HR+ human brain PET studies: an interscanner test-retest study.
    van Velden FH; Kloet RW; van Berckel BN; Buijs FL; Luurtsema G; Lammertsma AA; Boellaard R
    J Nucl Med; 2009 May; 50(5):693-702. PubMed ID: 19372482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT.
    Schain M; Tóth M; Cselényi Z; Arakawa R; Halldin C; Farde L; Varrone A
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):228-37. PubMed ID: 23076621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of HRRT and HR+ scanners for quantitative (R)-[11C]verapamil, [11C]raclopride and [11C]flumazenil brain studies.
    van Velden FH; Mansor SM; van Assema DM; van Berckel BN; Froklage FE; Wang S; Schuit RC; Asselin MC; Lammertsma AA; Boellaard R; Huisman MC
    Mol Imaging Biol; 2015 Feb; 17(1):129-39. PubMed ID: 25028091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.